SynthesisJournal of epidemiology and global health2026
Meta-Analysis of the Incidence and Influencing Factors of Malignant Tumors in Patients with Rheumatoid Arthritis.
Synthesis in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aims to systematically evaluate the incidence of malignant tumors in rheumatoid arthritis (RA) patients and identify influencing factors, providing an evidence-based foundation for early identification of high-risk groups and individualized management.
methodsCohort studies on tumor incidence and ifluencing factors in RA patients were searched in both Chinese and English databases from inception to July 31, 2025. Two researchers independently screened literature, extracted data, and assessed quality. Meta-analysis was performed using Stata 12.0 to calculate pooled incidence and hazard ratios (HR) with 95% confidence intervals (CI). The study is registered with Prospero (CRD420251141184).
resultsA total of 44 cohort studies involving 901,941 RA patients were included. The pooled incidence of malignant tumors was 4.1% (95%CI 3.3%-4.8%). Significant influencing factors were: age (HR 1.17, 95%CI 1.12-1.22), male sex (HR 1.58, 95%CI 1.23-2.04), smoking (HR 1.33, 95%CI 1.07-1.66), tumor necrosis factor inhibitor (TNFi) use (HR 0.80, 95%CI 0.66-0.97), abatacept use (HR 1.19, 95%CI 1.10-1.29), and comorbidities (HR 1.13, 95%CI 1.02-1.26), particularly lung disease (HR 2.17, 95%CI 1.48-3.17) and diabetes (HR 1.10, 95%CI 1.03-1.17). The following influencing factors without statistical significance are: body mass index(BMI), Non steroidal anti-inflammatory drugs(NSAIDs), methotrexate(MTX), biological disease-modifying antirheumatic drugs/targeted synthesis disease-modifying antirheumatic drugs(bDMARDs/tsDMARDs), interleukin-6 inhibitor(IL-6i), Janus kinase inhibitor(JAKi), glucocorticoid, serum-positive, diease duration.
conclusionAmong RA patients, older age, male sex, smoking, abatacept use, and comorbidities may be associated with increased tumor risk, while TNFi use may be associated with lower risk. Clinicians should consider these factors to identify high-risk populations for enhanced monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.